Antisense technologies have a future fighting neurodegenerative diseases

被引:16
作者
Seidman, S
Eckstein, F
Grifman, M
Soreq, H [1 ]
机构
[1] Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel
[2] Max Planck Inst Expt Med, D-37075 Gottingen, Germany
来源
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT | 1999年 / 9卷 / 04期
关键词
D O I
10.1089/oli.1.1999.9.333
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Our growing understanding of the role that unfavorable patterns of gene expression play in the etiology of neurodegenerative disease emphasizes the need for strategies to selectively block the biosynthesis of harmful proteins in the brain. Antisense technologies are ideally suited to this purpose. Tailor-designed to target specific RNA, antisense oligonucleotides and ribozymes offer tools to suppress the production of proteins mediating neurodegeneration. Although technical limitations must still be overcome, the antisense approach represents a novel and exciting strategy for intervention in diseases of the central nervous system.
引用
收藏
页码:333 / 340
页数:8
相关论文
共 70 条
  • [51] Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo
    Monia, BP
    Sasmor, H
    Johnston, JF
    Freier, SM
    Lesnik, EA
    Muller, M
    Geiger, T
    Altmann, KH
    Moser, H
    Fabbro, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (26) : 15481 - 15484
  • [52] A new peptide vector for efficient delivery of oligonucleotides into mammalian cells
    Morris, MC
    Vidal, P
    Chaloin, L
    Heitz, F
    Divita, G
    [J]. NUCLEIC ACIDS RESEARCH, 1997, 25 (14) : 2730 - 2736
  • [53] Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro
    Nakazono, K
    Ito, Y
    Wu, CH
    Wu, GY
    [J]. HEPATOLOGY, 1996, 23 (06) : 1297 - 1303
  • [54] Pardridge WM, 1998, J NEUROCHEM, V70, P1781
  • [55] Persico AM, 1998, NEUROSCIENCE, V82, P1115
  • [56] Cytosolic and nuclear delivery of oligonucleotides mediated by an amphiphilic anionic peptide
    Pichon, C
    Freulon, I
    Midoux, P
    Mayer, R
    Monsigny, M
    Roche, AC
    [J]. ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1997, 7 (04): : 335 - 343
  • [57] ENGINEERING OF HUMAN CHOLINESTERASES EXPLAINS AND PREDICTS DIVERSE CONSEQUENCES OF ADMINISTRATION OF VARIOUS DRUGS AND POISONS
    SCHWARZ, M
    GLICK, D
    LOEWENSTEIN, Y
    SOREQ, H
    [J]. PHARMACOLOGY & THERAPEUTICS, 1995, 67 (02) : 283 - 322
  • [58] The spread and uptake pattern of intracerebrally administered oligonucleotides in nerve and glial cell populations of the rat brain
    Sommer, W
    Cui, X
    Erdmann, B
    Wiklund, L
    Bricca, G
    Heilig, M
    Fuxe, K
    [J]. ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1998, 8 (02): : 75 - 85
  • [59] Controversies in the cellular pharmacology of oligodeoxynucleotides
    Stein, CA
    [J]. ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1997, 7 (03): : 207 - 209
  • [60] PROBLEMS IN INTERPRETATION OF DATA DERIVED FROM IN-VITRO AND IN-VIVO USE OF ANTISENSE OLIGODEOXYNUCLEOTIDES
    STEIN, CA
    KRIEG, AM
    [J]. ANTISENSE RESEARCH AND DEVELOPMENT, 1994, 4 (02): : 67 - 69